WuXi AppTec

Últimas noticias

Titulares en el idioma original de la fuente.

• 直击药明康德股东会：打完业绩翻身仗，还剩哪些“未知数”？ (se abre en una pestaña nueva)

  Moomoo · 1 oct 2026

• Top China Biopharma Stocks to Watch, According to Bernstein (se abre en una pestaña nueva)

  30 sept 2026

• 
  Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River (se abre en una pestaña nueva)

  29 sept 2026

• 药明康德(603259):无锡药明康德新药开发股份有限公司章程（2026年第二次修订） (se abre en una pestaña nueva)

  中财网 · 29 sept 2026

• 
  Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec (se abre en una pestaña nueva)

  GlobeNewswire · 24 sept 2026

• Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave (se abre en una pestaña nueva)

  24 sept 2026

• Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI (se abre en una pestaña nueva)

  23 sept 2026

• Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share (se abre en una pestaña nueva)

  23 sept 2026

• 
  Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market (se abre en una pestaña nueva)

  GlobeNewswire · 23 sept 2026

• 
  Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption (se abre en una pestaña nueva)

  GlobeNewswire · 23 sept 2026

• 
  Recent Price Trend in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) is Your Friend, Here's Why (se abre en una pestaña nueva)

  Zacks · 22 sept 2026

• Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption (se abre en una pestaña nueva)

  22 sept 2026

• Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions (se abre en una pestaña nueva)

  10 sept 2026

• Oligonucleotide Drug Delivery Is Moving Beyond the Liver (se abre en una pestaña nueva)

  3 sept 2026

• 
  WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion (se abre en una pestaña nueva)

  PR Newswire · 31 ago 2026

• 
  Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why (se abre en una pestaña nueva)

  Zacks · 27 ago 2026

• Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going (se abre en una pestaña nueva)

  11 ago 2026

• 
  Judge blocks US decision to add WuXi to list of firms tied to Chinese military (se abre en una pestaña nueva)

  Reuters · 7 ago 2026

• 
  WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model (se abre en una pestaña nueva)

  PR Newswire · 3 ago 2026

• 
  WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year (se abre en una pestaña nueva)

  PR Newswire · 22 jul 2026

• 
  China's WuXi sues US over allegations it supports Beijing's military (se abre en una pestaña nueva)

  Reuters · 11 jun 2026

• 
  WuXi AppTec hits back after being named in Pentagon’s Chinese military list (se abre en una pestaña nueva)

  Pharmaceutical Technology · 9 jun 2026

• 
  How The WuXi AppTec (SHSE:603259) Story Is Shifting With New Targets And Conviction Calls (se abre en una pestaña nueva)

  Simply Wall St. · 29 abr 2026